Clinical trial
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed…
NCT00028678 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00028678 |
|---|---|
| Title | Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme |
| Official title | A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Radiation |
| Interventions | dalteparin, radiation therapy |
| Enrollment | 45 |
| Start date | Jul 11, 2002 |
| Primary completion | Jul 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Feb 6, 2003 |
| Last update posted | Jun 18, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: